Geoffrey Sklar, MD, on integrating AI in a way that augments urologic care
On this video, Geoffrey N. Sklar, MD, FACS, recaps a session from the 2024 Stronger United Convention in Phoenix, Arizona titled, “Synthetic Intelligence in Urology”. Sklar is the chief medical officer for Chesapeake Urology and United Urology Group.
Video Transcript:
Synthetic intelligence is right here; it isn’t going away. There are plenty of angles on synthetic intelligence from it for imaging, for pathology, for even endoscopy. There’s now synthetic intelligence colonoscopy on the market. It will not be lengthy earlier than now we have synthetic intelligence-guided cystoscopy, ureteroscopy, these sorts of issues. How can we carry these issues in our apply and never add to the price or delay the remedy, however improve the remedy? That was the purpose of that.
There are different forms of AI which are popping out as nicely, issues to assist workflow. Issues like digital scribes, that means you will have a tool within the room that listens to the dialogue between the doctor and the affected person and helps generate the notes to lower the work of the doctor and precisely doc what was mentioned between the affected person and the doctor. There are plenty of techniques like that which are on the market. The attention-grabbing factor about all of them is that they’re very costly. There’s a little element of overpromising and underdelivering, as a result of they are saying that it could lower your workers. Now, we do not actually need to eliminate our workers. We love our workers. That is what retains us the place we’re, retains us environment friendly, retains us taking nice care. So, our purpose is how can we carry this in in an affordable approach that gives some benefit to the doctor and to the affected person.
One of many largest complaints from sufferers is that they hate it when docs sit in entrance of a pc and sort whereas they’re within the room. They need that 1 to 1 expertise, in order that they really feel that anyone listened to them. I feel that is what all these targets are to get that expertise. I might say we’re not fairly there. We’re getting there. Now we have tried 3 or 4 of those sorts [of] platforms. We will attempt extra, as a result of we do really feel that we have to get there. I feel people who find themselves simply saying, “we’re not going to go to AI at this level,” you are going to fall behind the bus right here. I do assume it’s worthwhile to keep forward. It is not low cost, even to do a trial. They usually need you to pay one thing to do a trial. I feel that is the longer term, and if we do not go down that path and we do not discover, we’re not going to make it higher for us and for the sufferers.
This transcript was AI generated and edited by human editors for readability.
